Haleon PLC Sponsored ADR $HLN Shares Sold by WealthTrust Axiom LLC

WealthTrust Axiom LLC trimmed its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 9.5% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 49,347 shares of the company’s stock after selling 5,193 shares during the period. WealthTrust Axiom LLC’s holdings in Haleon were worth $508,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in HLN. Bartlett & CO. Wealth Management LLC raised its stake in Haleon by 135.9% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company’s stock valued at $27,000 after purchasing an additional 1,491 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in Haleon in the 1st quarter valued at $29,000. Deutsche Bank AG raised its stake in Haleon by 267.8% in the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock valued at $32,000 after purchasing an additional 2,276 shares during the last quarter. Continuum Advisory LLC raised its stake in Haleon by 152.4% in the 1st quarter. Continuum Advisory LLC now owns 4,753 shares of the company’s stock valued at $49,000 after purchasing an additional 2,870 shares during the last quarter. Finally, Alpine Bank Wealth Management acquired a new position in Haleon in the 1st quarter valued at $56,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on HLN shares. Barclays reissued an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective for the company in a research note on Friday, May 9th. Wall Street Zen downgraded Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. BNP Paribas Exane raised Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective for the company in a research note on Tuesday, May 27th. Finally, BNP Paribas raised Haleon to a “strong-buy” rating in a research note on Tuesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Stock Down 0.1%

Shares of NYSE:HLN opened at $9.8050 on Monday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $9.93 and a two-hundred day moving average of $10.22. The stock has a market cap of $43.97 billion, a P/E ratio of 25.14, a PEG ratio of 2.90 and a beta of 0.23. Haleon PLC Sponsored ADR has a 52-week low of $8.86 and a 52-week high of $11.42.

Haleon Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be issued a $0.0555 dividend. This represents a yield of 190.0%. The ex-dividend date is Friday, August 15th. This is an increase from Haleon’s previous semi-annual dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 28.21%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.